Reviva Pharmaceuticals Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Brilaroxazine demonstrated robust, sustained efficacy and a superior safety profile in phase III trials for schizophrenia, with low relapse and discontinuation rates. Plans include a new proprietary formulation, extended patent life, and NDA filing by late 2028, with Nasdaq up-listing anticipated in 2027.
-
Brilaroxazine showed robust, durable efficacy and a favorable safety profile in phase III trials for schizophrenia, outperforming historical antipsychotics and addressing key unmet needs. A second phase III trial is planned, with NDA submission targeted for 2028 and potential exclusivity to 2046.
-
Brilaroxazine showed robust, sustained efficacy and safety in phase III schizophrenia trials, with minimal relapse and superior differentiation versus current antipsychotics. A second confirmatory trial is planned, with NDA filing targeted for early 2028 and potential patent exclusivity to 2046.
-
Brilaroxazine is advancing to a pivotal phase III trial for schizophrenia, with a new formulation designed to extend patent life to 2046. Pending FDA feedback, the company aims to expand indications and regain Nasdaq compliance, supported by a strong financial position and major upcoming catalysts.
-
Brilaroxazine is advancing to a second phase III trial in schizophrenia, with a new formulation aimed at extending patent life to 2046. FDA feedback on the formulation switch is expected mid-year, and the trial is set to start in Q3, leveraging strong prior data and a solid financial runway.
-
Brilaroxazine showed robust, sustained efficacy and a favorable safety profile in schizophrenia, with significant improvements in negative symptoms and low relapse rates. An additional phase 3 trial, required by the FDA, is set to begin soon, targeting NDA submission in late 2027.
Fiscal Year 2025
-
Brilaroxazine demonstrated robust efficacy, safety, and adherence in late-stage trials for schizophrenia, with strong expert endorsement of its differentiated profile and potential to address key unmet needs. FDA feedback in December will determine regulatory path.
-
The conference highlighted brilaroxazine's strong Phase 3 data in schizophrenia, with robust efficacy for negative symptoms, a favorable safety profile, and low discontinuation rates. Regulatory plans target an NDA filing in 2026, with competitive advantages over other late-stage assets.
-
Brilaroxazine demonstrated sustained efficacy in both positive and negative symptoms of schizophrenia over 12 months, with minimal weight gain, improved metabolic and hormonal profiles, and high adherence. Biomarker data suggest neuroprotective effects, and the safety profile is favorable compared to existing antipsychotics.
-
Brilaroxazine, in phase III for schizophrenia, showed robust efficacy for both primary and negative symptoms, superior adherence, and a favorable safety profile. Full data is expected in Q2 2025, with NDA submission targeted for end of 2026.
-
Brilaroxazine showed robust efficacy and safety in phase III schizophrenia trials, with low discontinuation and strong biomarker support. The drug's unique mechanism and anti-inflammatory effects position it for expansion into other neuropsychiatric and inflammatory indications.
-
Brilaroxazine demonstrated robust efficacy and safety in phase 3 schizophrenia trials, with lower discontinuation rates and significant improvements in negative symptoms compared to other antipsychotics. The company plans to expand indications and expects NDA submission in Q2 2026.
-
Brilaroxazine, a novel antipsychotic in phase III, showed robust efficacy and safety in treating schizophrenia, especially negative symptoms, with a 10-point separation from placebo and strong anti-inflammatory effects. NDA submission is planned for Q2 2026.
Fiscal Year 2024
-
Brilaroxazine showed rapid, robust efficacy in phase III schizophrenia trials, outperforming established antipsychotics on key endpoints and demonstrating strong safety and adherence. Novel vocal biomarker analysis validated clinical outcomes and is being integrated into ongoing studies, with regulatory interest supporting future adoption.